Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) PT at $54.63

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been given a consensus rating of “Buy” by the eleven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $58.5556.

Several equities research analysts have weighed in on MAZE shares. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Guggenheim raised their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Wells Fargo & Company began coverage on Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price for the company. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, Truist Financial initiated coverage on Maze Therapeutics in a report on Tuesday. They set a “buy” rating and a $68.00 price target on the stock.

Maze Therapeutics Trading Up 2.0%

Shares of NASDAQ MAZE opened at $49.43 on Friday. The firm’s 50-day moving average price is $45.68 and its 200-day moving average price is $36.59. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of -2.37 and a beta of 4.47. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $53.65.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. This trade represents a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 230,000 shares of company stock worth $9,768,292 over the last quarter.

Institutional Trading of Maze Therapeutics

Several institutional investors have recently added to or reduced their stakes in MAZE. Janus Henderson Group PLC grew its stake in shares of Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after acquiring an additional 915,342 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Maze Therapeutics by 3,868.5% during the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after acquiring an additional 758,104 shares during the last quarter. Caligan Partners LP purchased a new position in Maze Therapeutics during the 4th quarter valued at $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics during the 3rd quarter valued at $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.